Keap1-Nrf2
The Keap1-Nrf2 pathway is the major regulator of cytoprotective responses to oxidative and electrophilic stress.Although cytoprotection provided by Nrf2 activation is important for cancer chemoprevention in normal and premalignant tissues, in fully malignant cells Nrf2 activity provides growth advantage by increasing cancer chemoresistance and enhancing tumor cell growth Given that high Nrf2 activity commonly occurs in cancer cells with adverse outcomes, there is a need for therapies to inhibit Nrf2. Unfortunately, due to structural similarity with some other bZip family members, the development of specific Nrf2 inhibitors is a challenging task and only a few studies of Nrf2 inhibition have been published to date.
References
1.Emilia Kansanen et al. Redox Biology Volume 1, Issue 1, 2013, Pages 45-49
References
1.Emilia Kansanen et al. Redox Biology Volume 1, Issue 1, 2013, Pages 45-49
Nuclear Receptor/Transcription Factor
Keap1-Nrf2
-
VVD-130037
catalog no : M37603
cas no: 3034880-93-5
VVD-130037 is a small molecule activator specifically targeting Kelch-like ECH-associated protein 1 (KEAP1) with potential antitumor activity. -
Nrf2-IN-3
catalog no : M37217
cas no: 6325-13-9
Nrf2-IN-3 is a mKEAP1-selective NRF2 inhibitor that selectively binds KEAP1 mutants and restores their NRF2 inhibitory function by repairing the disrupted KEAP1/NRF2 interaction, and selectively sensitizes cisplatin in xenografts of mouse mKEAP1 cancer cells. -
L-Cystine dihydrochloride
catalog no : M35473
cas no: 30925-07-6
L-Cystine dihydrochloride is an Nrf2 inducer with whitening and anti-dark spot effects.L-Cystine dihydrochloride has cytoprotective effects in cells, and is often added to various fungal cultures as a carbon source. -
DDO-7263
catalog no : M35426
cas no: 2254004-96-9
DDO-7263 is a 1,2,4-Oxadiazole derivative that upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. -
CBR-470-1
catalog no : M35178
cas no: 2416095-06-0
CBR-470-1 is a potent inhibitor of glycolytic phosphoglycerate kinase 1 (PGK1) that activates NRF2 by increasing methylglyoxal levels.